One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Open Accesshttps://doi.org/10.1182/blood-2021-144576
Copy DOI Journal: Blood |  Publication Date: Nov 5, 2021 |
Affiliation: Novartis (Switzerland), Tris Pharma (United States), Sapienza University of Rome, Incyte (United States), Azienda USL di Bologna, Sahyadri Hospital, Hokkaido University Hospital, University of Freiburg, Fred Hutch Cancer Center, Biodonostia, First Pavlov State Medical University of St. Petersburg, St Vincent's Hospital Sydney, Moffitt Cancer Center, University Medical Center Hamburg-Eppendorf, Rambam Health Care Campus, Osaka UniversityPatient-Reported Outcomes (PROs) Among Patients With Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease (cGVHD) Randomized to Ruxolitinib (RUX) vs Best Available Therapy (BAT)
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
